Fidelity Investments
AMRX icon

Fidelity Investments’s Amneal Pharmaceuticals AMRX Stock Holding History

Fidelity Investments’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Buy
825,120
+33,110
+4% +$454K ﹤0.01% 1988
2026
Q1 		$9.84M Buy
792,010
+414,986
+110% +$5.57M ﹤0.01% 2052
2025
Q4 		$4.75M Buy
377,024
+83,453
+28% +$955K ﹤0.01% 2304
2025
Q3 		$2.94M Buy
293,571
+29,878
+11% +$268K ﹤0.01% 2402
2025
Q2 		$2.13M Sell
263,693
-40,312
-13% -$304K ﹤0.01% 2466
2025
Q1 		$2.55M Buy
304,005
+31,330
+11% +$262K ﹤0.01% 2367
2024
Q4 		$2.16M Buy
272,675
+69,165
+34% +$580K ﹤0.01% 2425
2024
Q3 		$1.69M Buy
203,510
+41,882
+26% +$328K ﹤0.01% 2445
2024
Q2 		$1.03M Buy
161,628
+12,201
+8% +$77.5K ﹤0.01% 2514
2024
Q1 		$906K Sell
149,427
-267
-0.2% -$1.51K ﹤0.01% 2535
2023
Q4 		$909K Sell
149,694
-5,918
-4% -$26.4K ﹤0.01% 2502
2023
Q3 		$657K Buy
155,612
+33,626
+28% +$125K ﹤0.01% 2560
2023
Q2 		$378K Buy
121,986
+555
+0.5% +$1.18K ﹤0.01% 2744
2023
Q1 		$169K Sell
121,431
-2,056
-2% -$4.09K ﹤0.01% 3045
2022
Q4 		$246K Buy
123,487
+658
+0.5% +$1.48K ﹤0.01% 2948
2022
Q3 		$248K Sell
122,829
-1,416
-1% -$3.97K ﹤0.01% 2993
2022
Q2 		$395K Sell
124,245
-8
-0% -$29 ﹤0.01% 2915
2022
Q1 		$518K Buy
+124,253
New +$550K ﹤0.01% 2979
2020
Q3 		– Sell
-77
Closed – – 3646
2020
Q2 		$0 Sell
77
-22
-22% -$91 ﹤0.01% 3553
2020
Q1 		$0 Hold
99
– – ﹤0.01% 3591
2019
Q4 		$0 Hold
99
– – ﹤0.01% 3753
2019
Q3 		$0 Sell
99
-10,056,869
-100% -$35.1M ﹤0.01% 3745
2019
Q2 		$72.1M Buy
10,056,968
+2,761,743
+38% +$28.2M 0.01% 1057
2019
Q1 		$103M Sell
7,295,225
-15,330
-0.2% -$203K 0.01% 892
2018
Q4 		$98.9M Sell
7,310,555
-2,728,554
-27% -$49.2M 0.01% 853
2018
Q3 		$223M Buy
10,039,109
+2,095,706
+26% +$44.1M 0.03% 630
2018
Q2 		$130M Buy
+7,943,403
New +$139M 0.02% 829

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Fidelity Investments's AMRX Position: Q2 2026 in Review

Fidelity Investments increased its Amneal Pharmaceuticals (AMRX) stake by 4.2% in Q2 2026, buying an estimated $454K and bringing the position to 825,120 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1988.

Fidelity Investments first reported a position in AMRX in Q2 2018 and has held it in 27 quarters since. The position peaked at $223M in Q3 2018. 308 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Fidelity Investments held 825,120 shares of Amneal Pharmaceuticals worth $14.3M as of Q2 2026.
  • Fidelity Investments bought 33,110 Amneal Pharmaceuticals shares in Q2 2026, an estimated $454K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1988 holding.
  • Fidelity Investments first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 27 quarters since.
  • Fidelity Investments's Amneal Pharmaceuticals position peaked at $223M in Q3 2018.
  • 308 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.